Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Aug 8, 2026, 13:56Cameron Horner: Whole Blood in Prehospital Care – What Does the Best Evidence Tell Us?
-
Aug 8, 2026, 13:52Carl Allen: New AAP Guidance Updates Pediatric Iron Deficiency Screening and Treatment
-
Aug 8, 2026, 13:39Augustina Isioma Ikusemoro: Platelet Inventory – The Most Unpredictable Balancing Act in Healthcare
-
Aug 8, 2026, 13:38João Gorgulho: Liquid Biopsy for Precision Immunotherapy in Hepatocellular Carcinoma
-
Aug 8, 2026, 13:33Emeka Patrick Chukwuka: Treatment Sequencing After JAK Inhibitor Failure in Relapsed and Refractory Myelofibrosis
-
Aug 8, 2026, 13:20Jhalak Patel: A Proud Milestone in Blood Banking and Transfusion Medicine
-
Aug 8, 2026, 09:56Same Drug, Different Results – ESC Working Group on Cardiovascular Pharmacotherapy
-
Aug 8, 2026, 09:37Maxime Dely: Behind Every Machine, There Is a Human Story
-
Aug 8, 2026, 09:30Veronica Sanchez: What You Need to Know About CKM Syndrome